论文部分内容阅读
目的:探讨甘精胰岛素联合格列美脲治疗2型糖尿病的临床疗效。方法:2型糖尿病患者60例,格列美脲1mg每日早餐前服用。甘精胰岛素睡前皮下注射,初始使用剂量为0.08~0.15IU/(kg·d),以空腹血糖(FBG)6.1mmoL/L为治疗目标值,每3~5d调整一次甘精胰岛素的剂量。结果:治疗12周后患者的FBG、2hPG和HbA1C均较治疗前有明显降低(P<0.05);治疗12周后患者FCP和PCP均较治疗前有明显升高(P<0.05)。治疗12周后FBG达标率为96.7%、2hPG达标率为83.3%(50/60)、HbA1C达标率为85.0%。本研究中仅1例患者出现轻度低血糖。结论:甘精胰岛素联合格列美脲治疗2型糖尿病,血糖达标率高,低血糖发生率低,患者对治疗的依从性好,是目前治疗2型糖尿病的优选方案。
Objective: To investigate the clinical efficacy of insulin glargine and glimepiride in the treatment of type 2 diabetes mellitus. Methods: Sixty patients with type 2 diabetes and glimepiride 1mg were taken daily before breakfast. Glargine is injected subcutaneously before bedtime at an initial dose of 0.08-0.15 IU / (kg · d). The fasting blood glucose (FBG) of 6.1 mmoL / L is taken as the therapeutic target, and the dosage of insulin glargine is adjusted every 3-5 days. Results: After 12 weeks of treatment, the FBG, 2hPG and HbA1C in patients were significantly lower than those before treatment (P <0.05). After 12 weeks of treatment, the FCP and PCP of patients were significantly higher than those before treatment (P <0.05). After 12 weeks of treatment, the FBG compliance rate was 96.7%, the 2hPG compliance rate was 83.3% (50/60), and the HbA1C compliance rate was 85.0%. Only one patient in this study developed mild hypoglycemia. CONCLUSION: Glargine and glimepiride are effective in treating type 2 diabetes mellitus with high blood glucose compliance rate, low incidence of hypoglycemia and good adherence to treatment.